Compare Jones Lang LaSalle Inc (JLL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Repligen Corporation Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.58B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Repligen Corporation Common Stock for 0 Days on average.
| JLL | RGEN | |
|---|---|---|
Market Cap | $13.58B | $11.31B |
Volume | 414,312 | 1,216,919 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $194.57 |
52-Week Low | $280.16 | $102.87 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.34B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $298.32, up 0.07% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 14.16 and P/S of 0.51, alongside consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M. Recent news highlights acquisitions and positive growth coverage, while analyst consensus is bullish with a $450.50 price target.
The outlook for JLL is positive based on earnings momentum and attractive valuation, though near-term technical weakness and reliance on real estate market cycles present risks. Upside potential exists if the company maintains its earnings beat streak and capitalizes on data center and global real estate growth trends highlighted in recent analyst reports.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
